I^ow-molecularr weight heparins (LMW'H) arc widely used in patients in whom anticoagulantt therapy is indicated and skin complications are considered to be rare. .
Introduction n Low-molecularr weight heparins (LMWH) are widely used in patients in whom anticoagulantt therapy is indicated. Side effects include bleeding, heparin induced thrombocytopenia,, and hypersensitivity reactions '. Skin complications due to LMWHH use are considered to be rare, but their incidence is likely to be underreportedd ~. 1 hey vary from an urticarial rash (type I immediate hypersensitivityy reaction), to erythematous lesions (delayed type IV hypersensitivity reaction)) and, exceptionally, skin necrosis.
LMWHH are considered safe and effective in pregnant and lactatmg women '\ In systematicc reviews of LMWH use during pregnancy or the postpartum period, the reportedd incidences of generalised skin reactions were low, i.e. 0.3% -0,6% ;u . We reportt here a remarkably higher rate of skin complications.
Methods s
Thee efficacy and safety of treatment with LMWH during pregnancy and the postpartumm period in consecutive women is evaluated in an ongoing prospective, observationall study in two university hospitals. Indications included thromboprophylaxiss in women with an increased risk for pregnancy-related YTL, treatment off VTL, and prophylaxis in women with mechanic heart valves. During scheduled follow-upp visits, data on pregnancy and drug-related complications were collected.
Alll patients were instructed to contact the study center in case of complications.
LMWHH were prescribed in body weight adjusted therapeutic dosages (75 antiXaa IU/kg per day) or in prophylactic dosages (less than 75 anli-Xa II/kg per day),, depending on the indication. laboratory measurements included among otherss platelet counts and anti-Xa levels. For calculating the incidence of complications.. Only the first episode was counted and subsequent episodes were censored.. Relative risks and their corresponding 95% confidence intervals (CI) weree calculated using SPSS software (version 9.0).
Results s
Untill the present interim analysis 66 pregnant or postpartum women were treated withh LMWH. Thirty-nine women received LMWH during the entire pregnancy andd postpartum period, 13 during pregnancy only, and 11 in the postpartum period onlv.. None of the women had a history of allergy to unfractionated heparin or IAIWTLL Besides folic acid, women were not using other drugs. inn one of these women using Danaparoid as third I.MWII symptoms persisted (see text). * All given inn therapeutic dosages. " 77 % was given as a therapeutic dosage onee woman (receiving Tinzaparin and Nadroparin (!)..)()() anti-Xa II Vml) as first andd second clioice, respectively) symptoms persisted during Danaparoid and labourr was induced in the 37 th week of gestation for this reason; the remaining patientt (receiving Nadroparin (19.000 anti-Xa IlJ/ml) and Nadroparin (9..>()() anti-Xaa IU/ml) as first and second clioice, respectively) switched to vitamin K antagonistss from the Hi' Ann alternative explanation for our observations could be pruritic urticarial papules andd plaques of 'pregnancy (PUPPP) '''. However, this common feature usually occurss during the last weeks ol pregnancy, and eruptions often become manifest withinn striae, which was different from the clinical picture in our patients.
Althoughh subcutaneous tests are considered to be the gold standard in case of delayedd hypersensitivity type IV skin reactions, there is no consensus about the optimall diagnostic strategy', and we preferred a pragmatic approach in the managementt of skin complications -.
Itt is of interest to note that pregnant women on the once-a-dav injection formulationn of nadroparin (19.000 anti-Xa If /nil) appeared to have an increased riskk of skin complications when compared to those using the lower concentration off the same preparation twice daily (observed difference: , (7.Ö-.58.1)).
Sincee these formulations contain the same substances, this observation cannot yett be understood.
Inn the absence of alternative and sale anticoagulants during pregnancy, LMWH remainn the treatment ol choice, but physicians should be aware of skin complications,, and should instruct patients properly. A pragmatic approach to switchh to another LMWH when skin complications occur seems appropriate, sincee the majority of the patients will tolerate the other LMWH.
